Clinical outcomes of encorafenib, binimetinib, and cetuximab for pretreated BRAF V600E-mutant metastatic colorectal cancer in the BEACON EAP follow-up study

被引：0
|
作者：
Kato, T. [1 ]
Kotani, D. [2 ]
Takashima, A. [3 ]
Satoh, T. [4 ]
Masuishi, T. [5 ]
Komatsu, Y. [6 ]
Shiozawa, M. [7 ]
Esaki, T.
Izawa, N. [8 ]
Takeuchi, S. [9 ]
Bando, H. [10 ]
Iwasa, S. [11 ]
Hasegawa, H. [12 ]
Yamaguchi, T. [13 ]
Taniguchi, H. [5 ]
Yamada, S. [14 ]
Yoshino, T. [2 ]
机构：
[1] Natl Hosp Org Osaka Natl Hosp, Dept Surg, Osaka, Japan
[2] Natl Canc Ctr Hosp East, Kashiwa, Japan
[3] Natl Canc Ctr Hosp, Dept Gastrointestinal Med Oncol, Chuo, Japan
[4] Kinki Univ, Dept Med Oncol, Sch Med, Osaka, Japan
[5] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Japan
[6] Hokkaido Univ Hosp, Div Canc Ctr, Sapporo, Japan
[7] Kanagawa Canc Ctr, Dept Gastrointestinal Surg, Yokohama, Japan
[8] St Marianna Univ, Dept Clin Oncol, Sch Med, Kawasaki, Japan
[9] Kanazawa Univ Hosp, Kanazawa, Japan
[10] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Onc, Kashiwa, Japan
[11] Natl Canc Ctr, Tokyo, Japan
[12] Natl Hosp Org Osaka Natl Hosp, Osaka, Japan
[13] Osaka Med & Pharmaceut Univ Hosp, Takatsuki, Japan
[14] Ono Pharmaceut, Osaka, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-23
引用
收藏
页码：S21 / S22
页数：2
相关论文
共 50 条
  • [1] Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer
    Shahjehan, F.
    Kamatham, S.
    Chandrasekharan, C.
    Kasi, P. M.
    DRUGS OF TODAY, 2019, 55 (11) : 683 - 693
  • [2] Effect of prior bevacizumab treatment in BRAF V600E-mutant metastatic colorectal cancer: Overall survival with encorafenib plus cetuximab plus /- binimetinib in BEACON CRC
    Aderka, D.
    Kopetz, S.
    Grothey, A.
    Van Cutsem, E.
    Yaeger, R.
    Wasan, H.
    Yoshino, T.
    Desai, J.
    Ciardiello, F.
    Golden, A.
    Edwards, M.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S214 - S214
  • [3] Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
    Van Cutsem, Eric
    Huijberts, Sanne
    Grothey, Axel
    Yaeger, Rona
    Cuyle, Pieter-Jan
    Elez, Elena
    Fakih, Marwan
    Montagut, Clara
    Peeters, Marc
    Yoshino, Takayuki
    Wasan, Harpreet
    Desai, C. Jayesh
    Ciardiello, Fortunato
    Gollerkeri, Ashwin
    Christy-Bittel, Janna
    Maharry, Kati
    Sandor, Victor
    Schellens, Jan Hm
    Kopetz, Scott
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (17) : 1460 - +
  • [4] Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (The BEACON CRC Study)
    Velez, L.
    Trevino, T.
    Kopetz, S.
    Grothey, A.
    Yaeger, R.
    Gollerkeri, A.
    Maharry, K.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S224 - S225
  • [5] Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC
    Kopetz, S.
    Grothey, A.
    Van Cutsem, E.
    Yaeger, R.
    Wasan, H.
    Yoshino, T.
    Desai, J.
    Ciardiello, F.
    Loupakis, F.
    Hong, Y. S.
    Steeghs, N.
    Guren, T. K.
    Arkenau, H-T
    Garcia-Alfonso, P.
    Belani, A.
    Zhang, X.
    Tabernero, J.
    ESMO OPEN, 2022, 7 (03)
  • [6] Safety and efficacy of encorafenib, binimetinib, plus cetuximab for BRAF V600E-mutant metastatic colorectal cancer: Results of a prospective study as an expanded access program
    Takashima, Atsuo
    Kotani, Daisuke
    Kato, Takeshi
    Satoh, Taroh
    Masuishi, Toshiki
    Komatsu, Yoshito
    Shiozawa, Manabu
    Esaki, Taito
    Izawa, Naoki
    Takeuchi, Shinji
    Bando, Hideaki
    Iwasa, Satoru
    Hasegawa, Hiroko
    Yamaguchi, Toshifumi
    Taniguchi, Hiroya
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [7] BEACON: A Randomised, Phase 3 Study of Encorafenib and Cetuximab plus /- Binimetinib vs. Choice of Either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-Mutant Metastatic Colorectal Cancer Patients
    Wasan, Harpreet
    Arkenau, Tobias
    Braun, Mike
    Samuel, Leslie
    Graham, Janet
    Kopetz, Scott
    Grothey, Axel
    Van Cutsem, Eric
    Yaeger, Rona
    Yoshino, Takayuki
    Desai, Jayesh
    Ciardello, Fortunato
    Gollerkeri, Ashwin
    Maharry, Kati
    Sandor, Victor
    Christy-Bittel, Janna
    Anderson, Lisa
    Tabernero, Josep
    BRITISH JOURNAL OF CANCER, 2019, 121 : 24 - 24
  • [8] Evaluating age as a factor for survival and quality of life in patients with BRAF V600E-mutant metastatic colorectal cancer treated with encorafenib plus cetuximab ± binimetinib: Subanalysis of BEACON CRC
    Ng, K.
    Ciardiello, F.
    Van Cutsem, E.
    Yaeger, R.
    Yoshino, T.
    Desai, J.
    Wasan, H.
    Alkuzweny, B.
    Zhang, X.
    Tabernero, J.
    Kopetz, S.
    ANNALS OF ONCOLOGY, 2022, 33 : S372 - S373
  • [9] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
    Sharma, Vinod
    Vanidassane, Ilavarasi
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09): : 876 - 876
  • [10] Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
    Roviello, Giandomenico
    D'Angelo, Alberto
    Petrioli, Roberto
    Roviello, Franco
    Cianchi, Fabio
    Nobili, Stefania
    Mini, Enrico
    Lavacchi, Daniele
    TRANSLATIONAL ONCOLOGY, 2020, 13 (09):
12345